Zobrazeno 1 - 10
of 12
pro vyhledávání: ''
Autor:
Masako Ichishi, Eri Usugi, Yoshifumi Hirokawa, Hiroshi Imai, Chise Matsuda, Masatoshi Watanabe, Kazuki Kanayama
Publikováno v:
Pathology International. 70:865-870
Human epidermal growth factor receptor 2 (HER2) protein overexpression is associated with HER2 gene amplification, a critical driver oncogenetic change in gastric cancer. HER2 heterogeneity in advanced gastric cancer is associated with a poor prognos
Autor:
Katsutoshi Seto, Masataka Haneda, Yoshitsugu Horio, Waki Hosoda, Yoshiko Murakami, Hiroaki Kuroda, Kenichi Okubo, Eiichi Sasaki, Shiro Fujita, Toyoaki Hida, Seiichi Kato, Katsuhiro Masago, Yasushi Yatabe
Publikováno v:
Pathology International. 70:253-261
BRAF mutations are rare driver mutations in non-small cell lung cancer (NSCLC), accounting for 1%-2% of the driver mutations, and the mutation spectrum has a wide range in contrast to other tumors. While V600E is a dominant mutation in melanoma, more
Autor:
Kyeng Won Yoon, Young Eun Joo, Jae Hyek Lee, Park Changhwan, Sung Kyu Choi, Hyun Soo Kim, Jong Sun Rew, Seok Ho Cho, Sung Bum Cho, Wan Sik Lee, Seon-Young Park
Publikováno v:
Pathology International. 60:203-211
Caspase 8 and survivin are known as key molecules of apoptosis in hepatocellular carcinoma (HCC). The purpose of the present study was to investigate the relationship between promoter methylation and expression and apoptotic function of caspase 8 and
Autor:
Itasu Ninomiya, Akishi Ooi, Takeru Oyama, Ryosuke Tajiri, Koichi Okamoto, Ritsuko Nakamura, Hiroko Ikeda
Publikováno v:
Pathology international. 65(11)
EGFR and ERBB2 belong to the EGFR gene family. In esophageal squamous cell carcinomas (SCCs), amplification of EGFR or ERBB2 is usually mutually exclusive. EGFR amplification occurs in approximately 15% of SCCs, ERBB2 occurs in less than 5%. Here, we
Autor:
Yasushi Kojima, Rumiko Watanuki-Miyauchi, Masanao Saio, Tsuyoshi Takami, Seiji Kasahara, Hisataka Moriwaki, Naoe Goto, Hisashi Tsurumi, Takeshi Hara
Publikováno v:
Pathology International. 55:324-330
Although diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, it is both clinically and morphologically heterogenous. The present study investigates the significance of survivin and a novel monoclonal antibody (MAb),
Publikováno v:
Pathology International. 55:53-62
The etiological role of human papillomavirus (HPV) in esophageal carcinoma (EC) in relation to p53, mdm2, p21(waf), c-erbB2 and the overall survival (OS) rate was investigated. Tumor and normal tissues from 50 EC were evaluated by polymerase chain re
Autor:
Yuko Hashimoto, Masafumi Abe, Hiroshi Hojo, Naoya Nakamura, Tetuo Kuze, Asumi Shirakawa, Yoshikazu Sasaki, Michiko Sato
Publikováno v:
Pathology International. 52:586-594
CD10, a proteolytic enzyme seen in germinal center cells and in the majority of follicular lymphomas, is occasionally expressed in diffuse large B-cell lymphomas (DLBCL). To clarify the origin and cellular characteristics of CD10-positive DLBCL, we a
Autor:
Masafumi Abe, Kunihiko Maeda, Kunihiko Tominaga, Michiko Sato, Yuko Hashimoto, Sayuri Hoshi, Tetsuo Kuze, Asumi Shirakawa, Naoya Nakamura, Yoshikazu Sasaki
Publikováno v:
Pathology International. 50:636-643
The immunoglobulin heavy chain gene (IgH gene) was analysed in four cases of B-cell Richter syndrome, in order to determine whether a secondary diffuse large B-cell lymphoma (DLBCL) could arise from the same clone as the initial B-cell chronic lympho
Autor:
Hui Zuo, Hironao Yasuoka, Ichiro Mori, Akira Miyauchi, Kennichi Kakudo, Ping Zhang, Yasushi Nakamura, Misa Nakamura
Publikováno v:
Pathology international. 57(1)
The BRAF V600E mutation has been identified in a high proportion of papillary thyroid carcinoma (PTC). In cell lines and a transgenic mouse model it has been demonstrated that the mutation constitutively activates the mitogen-activated protein kinase
Autor:
Dimitrios Iliopoulos, Aysegul Uner, Gulnur Guler, Peter McCue, Nilüfer Güler, Shuang-Yin Han, Kay Huebner
Publikováno v:
Pathology international. 55(8)
The FHIT and WWOX genes encompass the FRA3B and FRA16D fragile sites at chromosomes 3p14.2 and 16q23.3, respectively. Reduced Fhit and Wwox expression has been reported in approximately two-thirds of invasive breast tumors. Expression of these fragil